# US 2025/0375453 A1 · High-efficiency antimicrobial composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375453 A1
- Document ID: US20250375453A1
- Status: Published application
- Kind: A1
- Application number: 19/310,708
- Filed: 2025-08-26
- Published: 2025-12-11
- Earliest claimed: 2023-08-17
- Applicants: Cm4Cure S.A.
- Inventors: Cécile OURY; Patrizio LANCELLOTTI; Abdelhafid AQIL; Bartosz DITKOWSKI
- Web page: https://patentgrep.com/patent/US20250375453A1

## CPC

- A01N 43/90: having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A01N 43/647: Triazoles; Hydrogenated triazoles
- A01N 47/44: Guanidine; Derivatives thereof
- A01P 1/00: Disinfectants; Antimicrobial compounds or mixtures thereof
- A01P 3/00: Fungicides
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 38/06: Tripeptides
- A61L 15/44: Medicaments
- A61L 27/28: Materials for coating prostheses
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- C09D 5/14: Paints containing biocides, e.g. fungicides, insecticides or pesticides (C09D5/16 takes precedence)
- C09D 7/63: organic
- A61L 2300/206: Biguanides, e.g. chlorohexidine
- A61L 2300/406: Antibiotics
- A61L 2420/00: Materials or methods for coatings medical devices
- C08K 5/3472: Five-membered rings
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A01P: BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C09D: COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR (cosmetics A61K; processes for applying liquids or other fluent materials to surfaces, in general, B05D; staining wood B27K5/02; glazes or vitreous enamels C03C; natural resins, French polish, drying-oils, driers, turpentine, per se, C09F; polishing compositions other than French polish, ski waxes C09G; adhesives or use of materials as adhesives C09J; materials for sealing or packing joints or covers C09K3/10; materials for stopping leaks C09K3/12; processes for the electrolytic or electrophoretic production of coatings C25D)
- C08K: Use of inorganic or non-macromolecular organic substances as compounding ingredients (paints, inks, varnishes, dyes, polishes, adhesives C09)

## Abstract

New high-efficiency synergic or synergistic antimicrobial composition and application thereof. Medical device, biomaterial implants or bioprosthesis comprising the new high-efficiency antimicrobial composition incorporated in a coating or bulk distributed.

## Claims

### Claim 1

A synergic antimicrobial composition comprising a combination of Triazolo(4,5-d)pyrimidine derivative of formula (I)
wherein R1 is C3-5alkyl, R2 is a phenyl group substituted by one or more halogen atoms; R3 and R4 are both hydroxyl; R is XOH, wherein X is OCH2CH or a bond;
or a pharmaceutically acceptable salt thereof;
together with alexidine,
for use in prevention or treatment of infection or inflammation in a human or animal, preferably on human or animal skin.

### Claim 2 (depends on 1)

The synergic antimicrobial composition according to claim 1 characterized-in-that the ratio of Triazolo(4,5-d)pyrimidine derivative to alexidine (weight to weight ratio) is from 5:1 to 320:1; preferably from 5:1 to 40:1.

### Claim 3 (depends on 1, 2)

The synergic antimicrobial composition for use according to claim 1 or 2 characterized-in-that the Triazolo(4,5-d)pyrimidine derivative is (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-difluorophenyl)cyclopropylamino]-5-(propylthio)-3H-[1,2,3]-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol, also called Triafluocyl, and the triafluocyl concentration is from 10 μg/ml to 20 μg/ml, preferably from 20 μg/ml together with alexidine concentration of 0.25 μg/ml to 1 μg/ml, preferably 1 μg/ml.

### Claim 4 (depends on 1, 2, 3)

The synergic antimicrobial composition for use according to any one of claim 1 to 3 characterized-in-that the ratio of Triafluocyl to alexidine is between 5:1 to 20:1 for the infection or inflammation caused by Pseudomonas aeruginosa or 5:1 to 20:1 for the infection or inflammation caused by Candida albicans or 80:1 to 20:1 10:1 for the prevention or treatment of infection or inflammation caused by Staphylococcus aureus (MRSA).

### Claim 5 (depends on 1)

The synergic antimicrobial composition for use according to claim 1 characterized-in-that the Triazolo(4,5-d)pyrimidine derivative is (1S,2R,3S,4R)-4-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-1,2,3-cyclopentanetriol, also called Fluometacyl, and the ratio to alexidine is between (weight to weight ratio) 1:1 and 320:1 for the prevention or treatment of infection or inflammation.

### Claim 6 (depends on 5)

The synergic antimicrobial composition for use according to claim 5 characterised-in-that the Fluometacyl concentration is 0.5 to 20 μg/ml, with alexidine concentration from 2 μg/ml to 0.0625 μg/ml, preferably 2 μg/ml.

### Claim 7 (depends on 5, 6)

The synergic antimicrobial composition for use according to claims 5 or 6 characterized-in-that the ratio Fluometacyl to alexidine (weight to weight ratio) is 1:1 and 40:1 for the prevention or treatment of infection or inflammation caused by Staphylococcus aureus (MRSA) or 1.25:1 and 10:1 for the prevention or treatment of infection or inflammation caused by Pseudomonas aeruginosa or 5:1 and 20:1 for the prevention or treatment of infection or inflammation caused by Candida albicans.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

A medical device, biomaterial implants or bioprosthesis, particularly a catheter or a cardiovascular device, comprising the antimicrobial composition for use as defined in any one of claims 1 to 7 incorporated in a coating or bulk distributed.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7)

An ex-vivo method of microbial killing or prevention of microbial growth in biofilm formation comprising using, by applying on a surface, an effective amount or concentration of the composition for use a defined in any one of claims 1 to 7.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7)

An ex-vivo method of microbial killing or prevention of microbial growth in biofilm formation comprising, by applying in a polymeric coating on a surface, an effective amount or concentration of the composition for use as defined in any one of claims 1 to 7.

### Claim 11 (depends on 9, 10)

An ex-vivo method of microbial killing or prevention of microbial growth in biofilm formation according to claim 9 or 10 wherein the effective amount or concentration is in the range 0.5-20 mg/L of Triazolo(4,5-d)pyrimidine derivative and 0.01-5 mg/L of the alexidine.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7)

The synergic antibacterial composition for use according to any one of claim 1 to 7 characterized-in-that the infection or inflammation is caused by one or more of methicillin-resistant S. aureus (MRSA), methicillin-resistant S. epidermidis (MRSE), glycopeptide intermediate S. aureus (GISA), Coagulase-negative Staphylococci (CoNS), Vancomycin-resistant Enterococci (VRE), beta-hemolytic Streptococcus agalactiae (Group B Streptococcus, GBS); Acinetobacter spp., Acinetobacter baumannii, Bordetella pertussis, Campylobacter spp.; Enterobacteriaceae such as Citrobacter spp., Enterobacter spp., Escherichia co/i, Klebsiella spp., Salmonella spp., Serratia marcescens, Shigella spp., Yersinia spp.; Haemophilus influenza, Helocobacter pylorilegionella pneumophila, Neisseria spp., Pseudomonas aeruginosa, Vibrio cholera and the like; C. albicans, Aspergillus fumigatus, Cryptococcus neoformans, C. tropicalis, C. krusei or a mixture thereof.

### Claim 13

A synergic antibacterial composition comprising a combination of Triazolo(4,5-d)pyrimidine derivative of formula (I)
wherein R1 is C3-5 alkyl; R2 is a phenyl group substituted by one or more halogen atoms; R3 and R4 are both hydroxyl; R is OH; or a pharmaceutically acceptable salt thereof;
together with alexidine.

### Claim 14 (depends on 13)

The synergic antibacterial composition according to claim 13 wherein the Triazolo(4,5-d)pyrimidine derivative is (1S,2R,3S,4R)-4-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-1,2,3-cyclopentanetriol, also called Fluometacyl, and the ratio Fluometacyl to alexidine (weight to weight ratio) is between 1:1 to 320:1.

### Claim 15 (depends on 14)

The synergic antimicrobial composition according to claim 14 characterised-in-that Fluometacyl concentration is from 0.5 to 20 μg/ml with alexidine at concentration from 2 μg/ml to 0.00625 μg/ml, preferably 2 μg/ml, most preferably 0.5 μg/ml.

### Claim 16 (depends on 13, 14, 15)

A wound dressing comprising the antimicrobial composition according to any one of claims 13 to 15.
